Added to YB: 2026-02-17
Pitch date: 2026-02-13
NOVO-B.CO [neutral]
Novo Nordisk A/S
-21.54%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.1T
Pitch Price
DKK 301.92
Price Target
N/A
Dividend
4.94%
EV/EBITDA
7.46
P/E
10.29
EV/Sales
3.74
Sector
Pharmaceuticals
Category
special_situation
Show full summary:
Theodosian Capital | Stocks Update 13/2/2026 - NOVOB – License to Pill
NOVO-B.CO (update): FDA cracking down on compounded GLP-1s (like HIMS' generic Wegovy) will push demand to branded Novo/Lilly products. Trades 14.4x 2027 EPS, 3.7% yield - cheap vs pharma peers but needs to resolve challenges before re-rating higher.
Read full article (1 min)